The American Statistical Association and DIA have created an interdisciplinary working group of drug safety experts from academia, industry and regulatory backgrounds to explore the future direction for safety monitoring. This introduction to the series explains the background and rationale for this special section.
World Health Organization. The Importance of Pharmacovigilance—Safety Monitoring of Medicinal Products. Geneva, Switzerland: World Health Organization; 2002.
2.
MilaniAMazzoccoKStucchiS. How many research nurses for how many clinical trials in an oncology setting? Definition of the Nursing Time Required by Clinical Trial—Assessment Tool (NTRCT-AT). Int J Nurs Pract. 2017;23(1).
3.
FregoneseLEichlerI. The future of the development of medicines in idiopathic pulmonary fibrosis. BMC Med. 2015;13:239.
4.
WeeberFOoftSDijkstraKVoestE. Tumor organoids as a pre-clinical cancer model for drug discovery. Cell Chem Biol. 2017;24(9):1092–1100.
5.
RubinEGillilandDG. Drug development and clinical trials—the path to an approved cancer drug. Nat Rev Clin Oncol. 20112;9(4):215–222.
6.
TamNTHuyNTThoa leTB. Participants’ understanding of informed consent in clinical trials over three decades: systematic review and meta-analysis. Bull World Health Organ. 2015;93(3):186–98H.
O’NeillRT. Regulatory perspectives on data monitoring. Stat Med. 2002;21(19):2831–2842.
9.
WangWWhalenEMunsakaM. On quantitative methods for clinical safety monitoring in drug development. Stat Biopharm Res. 2017;10 (2): 85–97.
10.
MarchenkoOJiangQChuang-SteinC. Statistical considerations for cardiovascular outcome trials in patients with type 2 diabetes mellitus. Stat Biopharm Res. 2017;9(4):347–360.
11.
ZinkRCMarchenkoOSanchez-KamMIzemRJiangQ. Sources of safety data and statistical strategies for design and analysis: clinical trials. Therapeutic Innovation & Regulatory Science. 2018;52(2):141–158.
12.
IzemRSanchez-KamMMaHZinkRC. Sources of safety data and statistical strategies for design and analysis: post-market surveillance. Therapeutic Innovation & Regulatory Science. 2018;52(2):159–169.
13.
MarchenkoORussek-CohenELevensonMZinkRCKrukas-HampelMJiangQ. Sources of safety data and statistical strategies for design and analysis: real world insights. Therapeutic Innovation & Regulatory Science. 2018;52(2):170–186.
14.
MaHRussek-CohenEIzemRMarchenkoOVJiangQ. Sources of safety data and statistical strategies for design and analysis: Transforming data into evidence. Therapeutic Innovation & Regulatory Science. 2018;52(2):187–198.
